Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

558.87
+13.412.46%
Pre-market: 563.004.13+0.74%06:32 EDT
Volume:1.66M
Turnover:920.76M
Market Cap:60.34B
PE:14.09
High:583.28
Open:583.01
Low:542.89
Close:545.46
Loading ...

Regeneron price target lowered to $645 from $686 at Leerink

TIPRANKS
·
31 May

Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure

Dow Jones
·
31 May

BUZZ-U.S. STOCKS ON THE MOVE-RBB Bancorp, Seacoast, GATX

Reuters
·
31 May

Regeneron (REGN) Gets a Buy from Guggenheim

TIPRANKS
·
31 May

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-05-30

Reuters
·
30 May

Regeneron Down Over 16%, On Track for Largest Percent Decrease Since April 2011 -- Data Talk

Dow Jones
·
30 May

Regeneron (REGN) Gets a Buy from Morgan Stanley

TIPRANKS
·
30 May

US STOCKS-Wall St set for lower open as Trump says China violated tariff terms

Reuters
·
30 May

Sector Update: Health Care Stocks Fall Pre-Bell Friday

MT Newswires Live
·
30 May

Wells Fargo Downgrades Regeneron Pharmaceuticals to Equal Weight From Overweight, $580 Price Target

MT Newswires Live
·
30 May

Exchange-Traded Funds Mixed, Equity Futures Lower Pre-Bell Friday Amid US Tariff Reinstatement Decision

MT Newswires Live
·
30 May

Regeneron Stock (REGN) Retreats as Lung Disease Drug Data Disappoints

TIPRANKS
·
30 May

Regeneron Shares Slide On Mixed Trial Data For Smoker's Lung Drug

Reuters
·
30 May

BUZZ-Regeneron slumps after closely watched smoker's lung drug fails trial

Reuters
·
30 May

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

Dow Jones
·
30 May

Regeneron: Strong Financial Performance and Strategic Initiatives Drive Buy Rating with USD700 Target Price

TIPRANKS
·
30 May

BRIEF-Sanofi's AERIFY-1 Met Primary Endpoint, AERIFY-2 Did Not

Reuters
·
30 May

Sanofi Announces Mixed Results from Phase 3 Studies of Itepekimab for COPD Treatment

Reuters
·
30 May

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

GlobeNewswire
·
30 May

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
30 May